טוען...

The off-label use of targeted therapies in sarcomas: the OUTC’S program

BACKGROUND: Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies and yet there are potential treatment options for patients after standard treatment escape. The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to eval...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Cancer
Main Authors: Eberst, Lauriane, Cropet, Claire, Le Cesne, Axel, Pautier, Patricia, Penel, Nicolas, Adenis, Antoine, Chevreau, Christine, Bay, Jacques-Olivier, Collard, Olivier, Cupissol, Didier, Duffaud, Florence, Gentet, Jean-Claude, Piperno-Neumann, Sophie, Marec-Berard, Perrine, Bompas, Emmanuelle, Thyss, Antoine, Chaigneau, Loic, Cassier, Philippe, Bertucci, François, Blay, Jean-Yves, Ray-Coquard, Isabelle
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2014
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4289372/
https://ncbi.nlm.nih.gov/pubmed/25420707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-870
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!